Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:ATCCode |
gptkb:N07AA01
|
| gptkbp:CASNumber |
55-98-1
|
| gptkbp:chemicalFormula |
C12H19BrN2O2
|
| gptkbp:contraindication |
mechanical obstruction of the intestinal or urinary tract
|
| gptkbp:discoveredBy |
A. E. Bennett
|
| gptkbp:discoveredIn |
1931
|
| https://www.w3.org/2000/01/rdf-schema#label |
Neostigmine bromide
|
| gptkbp:IUPACName |
3-[(dimethylcarbamoyl)oxy]-N,N,N-trimethylanilinium bromide
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
gptkb:acetylcholinesterase_inhibitor
|
| gptkbp:meltingPoint |
147–153 °C
|
| gptkbp:molecularWeight |
303.20 g/mol
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
intramuscular
subcutaneous intravenous |
| gptkbp:sideEffect |
nausea
vomiting muscle cramps bradycardia increased salivation |
| gptkbp:synonym |
gptkb:Prostigmin
|
| gptkbp:usedFor |
gptkb:myasthenia_gravis
reversal of non-depolarizing neuromuscular blockade |
| gptkbp:bfsParent |
gptkb:neostigmine
|
| gptkbp:bfsLayer |
7
|